1.400USD+1.45%Mkt Cap: 375.56M $P/E: —1d ago
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypo…
Industry Peers
Drug Manufacturers - Specialty & Generic$65.19BUSDP/E 23.7
$22.46BUSDP/E 19.5
$20.18BUSD
$17.25BUSDP/E 26.4
$15.47BUSDP/E 179.2
$14.18BUSDP/E 29.7
$12.96BUSD
$8.93BUSDP/E 22.7
$7.80BUSD
$6.84BUSDP/E 25.1
$6.69BUSDP/E 442.8
$5.76BUSDP/E 48.8
$3.65BUSDP/E 19.0
$3.55BUSDP/E 11.3
$2.99BUSDP/E 20.9
$2.80BUSD
$2.52BUSDP/E 56.0
$2.35BUSDP/E 16.3
$2.40BUSDP/E 12.9
$2.31BUSD
$1.92BUSDP/E 19.4
$1.89BUSD
$1.86BUSDP/E 21.0
$1.71BUSD
$1.89BUSD
$1.67BUSD
$1.48BUSDP/E 17.5
$1.50BUSDP/E 124.1
$1.40BUSDP/E 14.8
$1.12BUSDP/E 35.4
$1.18BUSDP/E 17.6
$1.23BUSD
$1.06BUSDP/E Infinity
$1.02BUSD
$1.01BUSDP/E 196.9
$985.07MUSD
$918.60MUSDP/E 14.7
$873.22MUSDP/E 38.1
$875.69MUSDP/E 12.0
$819.46MUSDP/E Infinity
$668.29MUSD
$692.84MUSDP/E 161.5
$637.05MUSDP/E 6.2
$505.77MUSDP/E 14.3
$494.34MUSD
$447.41MUSD
$427.80MUSD
$396.78MUSD
$370.76MUSD
$355.90MUSD
$343.56MUSD
$357.30MUSD
$320.48MUSDP/E 43.7
$294.94MUSDP/E 15.2
$303.08MUSDP/E 9.7
$273.62MUSDP/E 49.1
$285.23MUSD
$250.29MUSDP/E 47.6
$255.34MUSDP/E 12.7
$236.39MUSDP/E 53.0
$206.95MUSDP/E 10.3
$210.49MUSD
$195.77MUSD
$185.67MUSD
$182.70MUSDP/E 8.8
$164.20MUSD
$143.26MUSDP/E 18.3
$146.07MUSD
$133.59MUSD
$126.10MUSD
$119.66MUSDP/E 18.6
$114.77MUSD
$83.73MUSDP/E 12.0
$94.75MUSD
$72.66MUSD
$67.25MUSD
$70.06MUSD
$62.42MUSDP/E 52.6
$63.44MUSDP/E 21.8
$60.48MUSD
$63.41MUSD
$53.86MUSD
$50.62MUSD
$49.37MUSD
$48.31MUSD
$42.20MUSD
$41.16MUSD
$33.86MUSDP/E Infinity
$31.75MUSD
$27.85MUSD
$26.87MUSD
$23.61MUSDP/E 204.0
$23.18MUSD
$22.62MUSD
$22.15MUSD
$18.56MUSD
$17.65MUSD
$14.93MUSD
$13.84MUSDP/E 16.8
$14.21MUSD
$11.64MUSD
$11.91MUSD
$9.88MUSD
$8.99MUSD
$8.21MUSD
$8.13MUSD
$6.05MUSDP/E 3.7
$6.17MUSD
$6.48MUSDP/E 0.3
$5.84MUSD
$5.46MUSDP/E Infinity
$3.29MUSDP/E 1.6
$2.01MUSD
$1.93MUSD
$2.08MUSDP/E 35.5
$1.54MUSD
$668.8KUSD
$173.7KUSDP/E 0.0
$175USD
Indicators:|
Key Statistics
Company
Market Cap375.56M $
Enterprise Value410.44M $
Revenue (TTM)232.40M $
Gross Profit196.73M $
Net Income (TTM)-5.34M $
Revenue/Share0.8770 USD
Last Price1.400 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees194
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS00972D1054
Valuation
P/E (Trailing)—
P/E (Forward)-7.37
PEG—
EV/EBITDA33.84
EV/Revenue1.77
P/S1.62
P/B13.73
EPS (TTM)-0.08
EPS (Forward)-0.19
52W Range
0.822718% of range4.040
52W High4.040 USD
52W Low0.8227 USD
Profitability
Gross Margin83.29%
Oper. Margin-2.76%
EBITDA Margin5.22%
Profit Margin-2.26%
ROE-16.39%
ROA-1.42%
Growth
Revenue Growth-6.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF67.99M $
CapEx (TTM)8.10M $
FCF Margin28.32%
FCF Yield17.52%
Net Debt34.88M $
Net Debt/EBITDA2.88
Balance Sheet
Debt/Equity1.59
Current Ratio1.40
Quick Ratio1.29
Book Value/Sh0.1020 USD
Cash/Share0.6060 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.200 USD
Upside (mean)+200.0%
Target Range3.000 USD – 6.000 USD
$3.000+200.0% to mean$6.000
# Analysts5
Ownership
Shares Out.268.26M
Float262.01M
Insiders4.06%
Institutions42.10%
Short Interest
Short Ratio3.1d
Short % Float7.26%
Short % Out.7.15%
Shares Short19.18M
Short (prev mo.)27.42M
Technical
SMA 501.123 (+24.6%)
SMA 2001.567 (-10.6%)
Beta0.23
S&P 52W Chg20.25%
Avg Vol (30d)5.46M
Avg Vol (10d)4.57M
Technical Indicators
RSI (14)69.3
MACD0.0932
MACD Signal0.0690
MACD Hist.+0.0242
BB Upper1.521 USD
BB Middle1.213 USD
BB Lower0.9048 USD
BB Width50.78%
ATR (14)0.0777 USD
Vol Ratio (20d)0.54x